Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy

Advanced non-small-cell lung cancer (NSCLC) remains a challenging disease. The limited utility of chemotherapy indicates the need for additional therapeutic options. Targeted therapy continues to be an important tool in the treatment of NSCLC. Mutations within the RAS–RAF–MEK–MAPK pathway, specifica...

Descripción completa

Detalles Bibliográficos
Autores principales: Weart, Thomas C, Miller, Kenneth D, Simone, Charles B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892608/
https://www.ncbi.nlm.nih.gov/pubmed/29662327
http://dx.doi.org/10.2147/CMAR.S142269
_version_ 1783313190794297344
author Weart, Thomas C
Miller, Kenneth D
Simone, Charles B
author_facet Weart, Thomas C
Miller, Kenneth D
Simone, Charles B
author_sort Weart, Thomas C
collection PubMed
description Advanced non-small-cell lung cancer (NSCLC) remains a challenging disease. The limited utility of chemotherapy indicates the need for additional therapeutic options. Targeted therapy continues to be an important tool in the treatment of NSCLC. Mutations within the RAS–RAF–MEK–MAPK pathway, specifically the BRAF V600E mutation, have become an important target for the subset of NSCLC patients with this mutation. This paper summarizes the clinical evidence that lead to the recent approval of the combination of dabrafenib and trametinib to treat patients with advanced NSCLC who harbor a BRAF V600E mutation.
format Online
Article
Text
id pubmed-5892608
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-58926082018-04-16 Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy Weart, Thomas C Miller, Kenneth D Simone, Charles B Cancer Manag Res Review Advanced non-small-cell lung cancer (NSCLC) remains a challenging disease. The limited utility of chemotherapy indicates the need for additional therapeutic options. Targeted therapy continues to be an important tool in the treatment of NSCLC. Mutations within the RAS–RAF–MEK–MAPK pathway, specifically the BRAF V600E mutation, have become an important target for the subset of NSCLC patients with this mutation. This paper summarizes the clinical evidence that lead to the recent approval of the combination of dabrafenib and trametinib to treat patients with advanced NSCLC who harbor a BRAF V600E mutation. Dove Medical Press 2018-04-03 /pmc/articles/PMC5892608/ /pubmed/29662327 http://dx.doi.org/10.2147/CMAR.S142269 Text en © 2018 Weart et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Weart, Thomas C
Miller, Kenneth D
Simone, Charles B
Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy
title Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy
title_full Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy
title_fullStr Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy
title_full_unstemmed Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy
title_short Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy
title_sort spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892608/
https://www.ncbi.nlm.nih.gov/pubmed/29662327
http://dx.doi.org/10.2147/CMAR.S142269
work_keys_str_mv AT weartthomasc spotlightondabrafenibtrametinibinthetreatmentofnonsmallcelllungcancerplaceintherapy
AT millerkennethd spotlightondabrafenibtrametinibinthetreatmentofnonsmallcelllungcancerplaceintherapy
AT simonecharlesb spotlightondabrafenibtrametinibinthetreatmentofnonsmallcelllungcancerplaceintherapy

Ejemplares similares